Journal of
Medicinal Chemistry
J. Med. Chem., 1996, 39(18), 3431-3434, DOI:10.1021/jm960340o

JM960340O

Supplementary material: Physical and Spectral Data for Compounds **1a**, **1b** and **1c**

Compound **1a**

mp 162-163.5 °C. (ether/hexane)

^{1}H NMR 300 MHz ($CDCl_3/D_2O$) δ 7.5-7.2 (m, 16 H), 7.00 (d, J=6.0 Hz, 4H), 5.04 (d, J=11.4 Hz, 2H), 4.79 (d, J=11.4 Hz, 2H), 3.96 (s, 2H), 3.78 (dd, J=11.7, 3.0 Hz, 2H), 3.63 (dd, J= 11.4, 3.0 Hz, 2H), 3.56 (s, 2H), 3.03 (dd, J= 14.1, 12.0 Hz, 2H)

^{13}C NMR (75 MHz, $CDCl_3/D_2O$) δ 137.82, 136.80, 129.40, 128.93, 128.56, 128.14, 128.05, 127.05, 76.58, 76.36, 74.95, 66.95, 31.76

UV (methanol) λ = 258.6 nm, ε = 780

Anal. Calcd. for $C_{34}H_{36}SO_6$: C, 71.30; H, 6.34
Found: C, 71.20; H, 6.35.

****

Compound **1b**
Bis methanesulfonate salt tetrahydrate amorphous solid

^{1}H NMR (500 MHz , DMSO) δ 7.52 (t, J=7.5 Hz, 2H), 7.44 (d, J=8.0 Hz, 2H), 7.35-7.2 (m, 12H), 7.11 (d, J=7.5 Hz, 2H). 4.93 (d, J=12.3 Hz, 2H), 4.88 (d, J= 12.2, 2H), 3.67 (dd, J= 11.2, 3.4 Hz, 2H), 3.39 (dd, J= 13.6, 2.9 Hz, 2H), 2.99 (dd, J= 13.7, 11.8 Hz, 2H), 2.35 (s, 6H)

^{13}C NMR via HMQC (125 MHz, DMSO) δ 130.45, 129.8, 129.67, 127.63, 126.4, 121.66, 121.18, 78.63, 75.69, 74.30, 67.12, 39.78, 32.06

UV (50% acetonitrile/ pH7 potassium phosphate) λ 239 nm ε = 15000

Anal. Calcd. for $C_{34}H_{38}SO_6N_2 \cdot 2CH_4SO_3 \cdot 4H_2O$: C, 49.87; H, 6.28; N, 3.23.
Found: C, 49.40; H, 5.65; N, 3.22

****

Compound **1c**

m.p. 96-98° C (benzene)

^{1}H-NMR (500 MHz, $CDCl_3$) δ 8.85 (s, 1H); 7.83 (s, 1H); 7.35 (m, 3H); 6.99 (d, J=7.5 Hz, 2H); 5.26 (d, J=11.0 Hz, 1H); 5.01 (d, J=12.0 Hz, 1H); 4.00 (s, 1H); 3.74 (dd, J= 14.0, 2.0 Hz, 1H); 3.65 (dd, J= 14.0, 2.0 Hz, 1H); 3.00 (dd, J= 12.0, 14.0 Hz, 1H).

UV (methanol) λ 240 nm ε = 8330

Anal. Calcd. for $C_{28}H_{30}S_3O_6N_2 \cdot H_2O$: C, 55.61; H, 5.33; N, 4.63
Found: C, 55.55; H, 5.17; N, 4.51



1

Figure 1. Structures of protease inhibitors.